Mon, 10 Dec 2018 12:00:00 EST Clinical Decision Support Algorithm to Predict Diabetic Retinopathy Condition: Diabetic Retinopathy Intervention: Other: risk factors for diabetic retinopathy Sponsors: Oklahoma State University Center for Health Sciences; Oklahoma State University; University of Oklahoma Not yet recruiting
Mon, 10 Dec 2018 12:00:00 EST Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg Duvie Conditions: Type 2 Diabetes Mellitus; Inadequate Glucose Control Intervention: Drug: duvie Sponsors: Pusan National University Hospital; Chong Kun Dang Pharmaceutical Corp. Not yet recruiting
Mon, 10 Dec 2018 12:00:00 EST Teneligliptin and Atorvastatin DDI Study Condition: Diabete Mellitus Interventions: Drug: Teneligliptin; Drug: Atorvastatin; Drug: Teneligliptin + Atorvastatin Sponsor: Handok Pharmaceuticals Co., Ltd. Not yet recruiting
Mon, 10 Dec 2018 12:00:00 EST The Effect of GIP(3-30)NH2 Condition: Increasing Insulin Interventions: Other: GIP receptor antagonist; Other: GIP receptor agonist; Other: Saline Sponsors: University Hospital, Gentofte, Copenhagen; Steno Diabetes Center; University of Copenhagen Active, not recruiting
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.
Wed, 28 Nov 2018 15:38:00 -0500 FDA approves first biosimilar for treatment of adult patients with non-Hodgkin’s lymphoma The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin’s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.
